Answers are grounded in this paper and cite their sources.
The CDK4/6 inhibitor, abemaciclib, is now the standard of care adjuvant therapy for patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) tumors at high risk of recurrence. Real-world usage uncovers emerging side effects that may have been previously unreported in clinical trials. Here, we present the clinical course of a patient who developed a syndrome of inappropriate antidiuretic hormone (SIADH) without underlying kidney injury due to abemaciclib use.
No takes yet. Share an insight, caveat, or question.
Carleton et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: